+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Immunotherapy. Sensitizing Agents for Cancer Resistant to Cell Mediated Immunotherapy

  • ID: 5130633
  • Book
  • January 2021
  • 250 Pages
  • Elsevier Science and Technology
1 of 3
Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Immunotherapy discusses current and under investigation treatments in pancreatic cancer. The book presents information on how to combine current therapy with treatment under development and/or in clinical trials in order to improve survival. Chapters review new modalities to cure oncolytic viruses and Bi-specific T cell engager (BiTEs) as future clinical treatments, along with discussions on recent research using those modalities in combination therapy. The book is a valuable source for cancer researchers, oncologists and other members of the medical and biomedical field who are interested in learning more about new therapies.
  • Discusses oncolytic virus in pancreatic cancer use, mainly herpes and adenoviruses, the results obtained on basic research, and clinical trials
  • Encompasses knowledge on Bi-specific T cell engager (BiTEs), focusing on its function, development and use on pancreatic cancer
  • Brings information on recently developed combination therapies that allow for a lower dose of treatment and hence less side effects
Note: Product cover images may vary from those shown
2 of 3
1. Pancreatic cancer generalities, current surgical treatment, updates
2. Current chemotherapy and immunotherapy in pancreatic cancer
3. Generalities of Oncolytic virus and HF10 in pancreatic cancer
4. Oncolytic Adenovirus use in pancreatic cancer
5. BiTE cell generalities and its potential use for pancreatic cancer
6. Precision oncology for pancreatic cancer
7. Strategies with immune therapy
8. Combination therapies of current/ new options to treat pancreatic cancer in future
Note: Product cover images may vary from those shown
3 of 3
Hideki, Kasuya
Dr Kasuya Hideki has graduated from medical career on 1990 at Aichi Medical University, Japan. He did his residency in general surgery, transplantation surgery and liver-pancreas surgery in Nagoya University, Japan. He also has experience in research including research fellowship at the division of surgical oncology at Massachusetts General Hospital, Harvard Medical School. Since then he is being involved in clinical as well as research work with focus on oncolytic virus, including its use, its generation and combination therapies with current approved therapies. In 2015, he started the laboratory of cancer immune therapy research center at Nagoya University as Chairman where he continues to do research on oncolytic virus and its use on pancreatic cancer.
Bustos Villalobos, Itzel
Dr Itzel Bustos Villalobos has graduated from medical career on 2002 from La Salle University, Mexico. She did internship in pediatrics and completed her PhD in pediatric oncology at the University of Nagoya, Japan. Posteriorly she did research in melanoma at the University of California, Davis with a broad experience in cancer immunology. Currently she works for the University of Nagoya at the Cancer Immune Therapy Research Center where she continues doing research on oncolytic virus in diverse types of cancer.
Note: Product cover images may vary from those shown